Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study.

[1]  E. Burnside,et al.  A logistic regression model based on the national mammography database format to aid breast cancer diagnosis. , 2009, AJR. American journal of roentgenology.

[2]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[3]  S. Alberts,et al.  Chemotherapy for colorectal cancer liver metastases. , 2008, The oncologist.

[4]  Ram D. Sriram,et al.  Imaging as a Biomarker: Standards for Change Measurements in Therapy workshop summary. , 2008, Academic radiology.

[5]  F. Impellizzeri,et al.  Convergent Evidence for Construct Validity of a 7-Point Likert Scale of Lower Limb Muscle Soreness , 2007, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[6]  Carl J D'Orsi,et al.  BI-RADS decoded: detailed guidance on potentially confusing issues. , 2007, Radiologic clinics of North America.

[7]  L. Schwartz,et al.  Lung cancer: computerized quantification of tumor response--initial results. , 2006, Radiology.

[8]  L. Schwartz,et al.  Imaging response assessment in oncology , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[9]  Rabiya S Tuma,et al.  Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. , 2006, Journal of the National Cancer Institute.

[10]  M. Rosen,et al.  Primer on imaging technologies for cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Mainiero,et al.  BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. , 2006, Radiology.

[12]  Daniel C Sullivan,et al.  Functional imaging in lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[14]  James H Thrall,et al.  Using imaging biomarkers to accelerate drug development and clinical trials. , 2005, Drug discovery today.

[15]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[16]  Constantine Gatsonis,et al.  Primer on multiple regression models for diagnostic imaging research. , 2003, Radiology.

[17]  James H Thrall,et al.  Biomarkers in imaging: realizing radiology's future. , 2003, Radiology.

[18]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Rebecca S Lewis,et al.  Does training in the Breast Imaging Reporting and Data System (BI-RADS) improve biopsy recommendations or feature analysis agreement with experienced breast imagers at mammography? , 2002, Radiology.

[20]  Curtis P Langlotz,et al.  Automatic structuring of radiology reports: harbinger of a second information revolution in radiology. , 2002, Radiology.

[21]  Kurt Lohman,et al.  Interpreting measures of treatment effect in cancer clinical trials. , 2002, The oncologist.

[22]  P. Black,et al.  The Use of a Simple Likert Scale to Measure Quality Of Life In Brain Tumor Patients , 2001, Journal of Neuro-Oncology.

[23]  H. White,et al.  Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. , 2001, Journal of clinical epidemiology.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[26]  R. Likert.  “Technique for the Measurement of Attitudes, A” , 2022, The SAGE Encyclopedia of Research Design.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.